| Literature DB >> 26101225 |
Brooke M Rock1, Mark E Tometsko1, Sonal K Patel1, Kevin J Hamblett1, William C Fanslow1, Dan A Rock2.
Abstract
Antibody drug conjugates are emerging as a powerful class of antitumor agents with efficacy across a range of cancers; therefore, understanding the disposition of this class of therapeutic is crucial. Reported here is a method of enriching a specific organelle (lysosome) to understand the catabolism of an anti-CD70 Ab-MCC-DM1, an antibody drug conjugate with a noncleavable linker. With such techniques a higher degree of concentration-activity relationship can be established for in vitro cell lines; this can aid in understanding the resultant catabolite concentrations necessary to exert activity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26101225 DOI: 10.1124/dmd.115.064253
Source DB: PubMed Journal: Drug Metab Dispos ISSN: 0090-9556 Impact factor: 3.922